New hope for rare blood cancer: lenalidomide dose study shows promise
NCT ID NCT02302469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug lenalidomide in 17 people with Waldenstrom macroglobulinemia, a rare blood cancer, that had returned or stopped responding to prior treatments. The main goal was to find the safest dose by monitoring side effects. Researchers also looked at how many patients responded to the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH LENS
Lens, 62307, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier de la côte basque
Bayonne, 64109, France
-
Ch Clermond Ferrand
Clermont-Ferrand, 63000, France
-
Ch Nantes
Nantes, 44 093, France
-
Chru Lille
Lille, 59037, France
-
Groupe hospitalier Pitié Salpétrière
Paris, 75651, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Smartwatches track hidden heart risk in blood cancer patients
- Can a tailored exercise and diet plan beat cancer fatigue?
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug duo shows promise for rare blood cancer